Adult-onset beta-thalassaemia intermedia caused by a 5-Mb somatic clonal segmental deletion in haemopoietic stem cells involving the b-globin locus Beta-thalassaemia major is amongst the most severe common monogenic diseases worldwide and, with few exceptions, is due to inheritance two defective beta-globin (HBB) genes in a Mendelian fashion. Heterozygous individuals, inheriting a single defective allele, are usually clinically asymptomatic. This study describes the molecular genetic investigation in a patient with an adult-onset and progressively worsening anaemia, culminating in a condition comparable with transfusion-dependent beta-thalassaemia. The female patient, born in 1962, self-reported as an asymptomatic beta-thalassaemia heterozygote in infancy, childhood and adolescence. In 1991 she reported having anaemia and moderate splenomegaly following the uncomplicated delivery of her second child. In 1996, she presented with severe anaemia [haemoglobin (Hb) 49 g/l, mean cell haemoglobin 23 pg, mean cell volume 76 fl], raised HbA 2 (4Á5%) and HbF (12%), with nucleated red blood cells (11/100 white cells) and reticulocytosis (5%). DNA analysis of peripheral leucocytes identified heterozygosity for a single beta-thalassaemia mutation HBB:c.315+1G>A (IVSII-1G>A) in the patient and her father (the latter with haematology consistent with heterozygous beta-thalassaemia). Her mother had normal haematology and HBB genes. Variants in the alphaglobin genes and gene-cluster were excluded in all family members. All initial haematology and DNA studies were performed by standard methods (Traeger-Synodinos et al, 2015) : ferritin, folic acid and vitamin B12 levels were within normal range, with mild indirect hyperbilirubinemia (30Á8 µmol/l), and a negative Coombs test (direct and indirect). Bone marrow biopsy found marked erythroid hyperplasia, without myelodysplasia. Paroxysmal nocturnal haemoglobinuria was excluded (Ham test and flow cytometry). A 51 Cr-labelled red blood cell (RBC) survival study demonstrated a RBC half-life of 11Á5 days, without splenic sequestration. The patient began regular transfusions (3-4 units of packed RBCs/month) when aged 34 years; her transfusion requirements then remained unchanged, following a splenectomy in 1997, and a trial with weekly subcutaneous recombinant erythropoietin. In 2007 a portal vein thrombosis was treated with heparin, followed by long-term warfarin. Hypercoagulability evaluation was negative, and the thrombosis was attributed to haemolytic anaemia, along with a markedly elevated platelet count secondary to splenectomy. Anagrelide was initiated to reduce the number of platelets. The patient was managed with folic acid replacement and iron chelation therapy (Deferasirox), to maintain ferritin around 1000 µg/l. Magnetic resonance imaging excluded clinically significant liver and heart iron levels.
In 2015, repeat DNA analysis by Sanger sequencing was performed on leucocyte DNA, along with DNA from oral mucosal epithelia and hair follicles. Although the IVSII-1G>A mutation was confirmed in leucocyte DNA, the ratio of normal (G) versus variant (A) was skewed, with extremely low levels of normal allele. DNA from oral mucosal epithelium and hair follicles showed classic heterozygosity for IVSII-1G>A ( Fig 1A, 1 ). Following this result, peripheral blood DNA was analysed for genomic copy number variations (CNVs) using the Affymetrix CytoScan HD Array and Chromosome Analysis Suite (ChAS, version 3.2) software (Thermo Fisher Scientific, Santa Clara, CA, USA) (Gijsbers et al, 2009) . A heterozygous deletion of 4Á97 Mb (hg19/GRCh37: 1, 313, 792-6, 287, 277) was identified on chromosome (chr) 11 (11p15.5p15.4) showing a skewed ratio of 90% deletion vs. 10% normal (Fig 1) . CNV analysis on peripheral blood DNA from the mother (the father is now deceased), excluded any deletions in chr11p15.5p15.4. The array results from the patient and her mother were evaluated to determine the parental origin of the deletion. The 4Á97 Mb deletion region included 1608 single nucleotide polymorphisms (SNPs). Of the 1227 SNPs homozygous in the propositus (informative), 376 (30%) were absent in the mother, indicating that the 4Á97 Mb deletion involves the maternally inherited allele, which harbours the normal HBB gene (the region flanking the 4Á97 Mb deletion showed biallelic distribution of SNPs). Thus, the DNA in the patient's peripheral blood is hemizygous for the paternally inherited beta-thalassaemia mutation.
The typical heterozygosity (50%) for the beta-thalassaemia mutation in DNA from the patient's hair follicles and oral mucosal cells suggests a somatic origin of the segmental deletion, affecting (at least) the haemopoietic cells. The late onset of beta-thalassaemia intermedia indicates a preferential survival of the haemopoietic cells containing the deleted region, which have become the main source of erythropoiesis.
Previous cases of late-onset beta-thalassaemia have been described (Badens et al, 2002; Galanello et al, 2004; Chang et al, 2008; Harteveld et al, 2013; Bento et al, 2013) . Two molecular mechanisms are distinguishable: segmental duplication of the paternal chr 11p allele (mosaic segmental uniparental isodisomy) or mosaic deletion of the maternal allele , the array data are shown in detail for the p-telomeric part of chromosome 11 for the propositus (in blue; AR1500073) and mother (in pink; AR1500074). From the top, the first and third (blue) and second and fourth line (pink) respectively represents patient and mother's copy number of the probes that indicate the presence or absence of a DNA fragment. This can be interpreted as partial loss of one copy in the patient for the region indicated above as a red bar (4Á97 Mb). The 5th and 6th line represent the single nucleotide polymorphisms (SNPs) in the same region, which can be either homozygous for the one variant [AA, B-allele frequency (BAF) = 0], heterozygous (AB, BAF = 0Á5) or homozygous for the other variant (BB, BAF = 1), seen as three lines in the normal (two alleles). The mother shows a normal distribution. The patient on the other hand shows four lines in the deleted area, indicating hemizygosity for the SNP's present (>90% mosaic) and an almost complete deletion of the maternally-inherited allele. (Table I) , with respective homozygosity or hemizygosity for the mutated paternal HBB allele in haemopoietic cells. Although a meaningful comparison the data between cases is hampered by the heterogeneity of methods, CNV nomenclature and stage of disease at analysis, the date indicates that the CNV in our case was amongst the smallest (~5Mb) and the level of deleted allele relative to normal amongst the highest (>90%).
Deteriorating clinical expression in all cases implies that cells with maternal segmental allelic loss or paternal homozygosity have a selective advantage over cells biallelic for chr 11p15. However, underlying mechanisms are not apparent. In our patient the deleted region contains 124 Ensembl coding genes, including 14 Online Mendelian Inheritance in Manâ Morbid genes (CTSD, TNNI2, TNNT3, IGF2, INS, TH, CD81, KCNQ1, CDKN1C, SLC22A18, PGAP2 and STIM1), the b-globin gene cluster (HBB, HBD, HBG1, HBG2 and HBE) and imprinted genes, including H19 and IGF2 (exclusively transcribed from the maternal allele or paternal allele, respectively). It could be postulated that if the maternally-active growth suppressor gene H19 is lost, the paternally-active growth-enhancer gene, IGF2, is left unregulated. This mechanism is observed in 20% of Beckwith-Wiedemann patients with uniparental isodisomy of 11p, characterized by cellular over-growth and a predisposition to tumour development. A single case has been reported of a congenital Beckwith-Wiedemann Syndrome with a beta-thalassaemia major phenotype, despite inheriting only a single beta-thalassaemia mutation, carried by his father (Beldjord et al, 1992) .
Overall cases of late-onset of beta-thalassaemia major or sickle cell disease are extremely rare, but based on the handful of cases described to date, molecular investigation should primarily consider somatic paternal uniparental isodisomy or maternal loss of chr 11p15, and analysis of the HBB gene mutations should not be restricted to the blood, but also be extended to the investigation of DNA from other tissues.
